NASDAQ: NSPR · Industrial Applications and Services · 5 alerts · CIK 1433607
Share price
$0.6000Close, Nov 16
Market cap
$32.5M
Shares outstanding
54.13MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All InspireMD, Inc. filings on SEC EDGAR ↗
InspireMD reported a net loss of $37.8 million for the nine months ended September 30, 2026, compared to $37.0 million in the prior year period. While revenues grew to $7.4 million from $5.8 million year-over-year, the company experienced a significant decrease in cash and marketable securities, ending the period with $19.2 million in cash.
InspireMD, Inc. priced an underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $37.5 million. The offering includes 7,342,308 shares of common stock and pre-funded warrants for 50,350,000 shares, each accompanied by Series L warrants. Proceeds are intended for research and development, sales and marketing, and general corporate purposes.
InspireMD reported third quarter 2026 financial results, highlighted by total revenue of $2.2 million, a 9% increase year-over-year driven by international performance. During the quarter, the company received FDA approval for its CGuard Prime carotid stent system for TCAR procedures, which is expected to double its U.S. addressable market with a commercial launch planned for Q4 2026.
Term
Q3 2026
“FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-g”
InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.